» Articles » PMID: 36986084

In Vitro Probiotic Properties of Subsp. SF and Its Alleviating Effect on Non-Alcoholic Fatty Liver Disease

Overview
Journal Nutrients
Date 2023 Mar 29
PMID 36986084
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease with many influencing factors. With the increasing role of the gut-liver axis in various liver diseases, research on the prevention and treatment of NAFLD with probiotics is increasing. In the present study, a subsp. strain, SF, was isolated from the feces of healthy infants and characterized by sequencing of the 16S rDNA. A systematic probiotic evaluation was carried out, and a diet-induced mouse model was constructed to study the effect and mechanism of SF on diet-induced NAFLD. Results show that SF has excellent gastrointestinal fluid tolerance and intestinal colonization, and strong antibacterial and antioxidant capabilities. In vivo, SF modulated intestinal flora, restored the intestinal barrier, and inhibited LPS entrance into the portal circulation, which subsequently inhibited the TLR4/NF-κB and modulated the PI3K-Akt/AMPK signaling pathway, attenuated the inflammatory response, and reduced lipid accumulation. In addition, SF attenuated oxidative stress and further alleviated autophagy, resulting in an ameliorative effect on NAFLD. Therefore, our study provides a new dietary method for the treatment of NAFLD.

Citing Articles

Serum uric acid and nonalcoholic fatty liver disease.

Fan J, Wang D Front Endocrinol (Lausanne). 2024; 15():1455132.

PMID: 39669496 PMC: 11635646. DOI: 10.3389/fendo.2024.1455132.


Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of and in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity.

Lu J, Shataer D, Yan H, Dong X, Zhang M, Qin Y Foods. 2024; 13(18).

PMID: 39335920 PMC: 11431124. DOI: 10.3390/foods13182992.


Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease.

Li Y, Li X, Duan H, Yang K, Ye J Front Immunol. 2024; 15:1398652.

PMID: 38779682 PMC: 11109441. DOI: 10.3389/fimmu.2024.1398652.


The Impact of Probiotic on Liver Diseases and the Microbiota.

Hizo G, Rampelotto P Life (Basel). 2024; 14(2).

PMID: 38398748 PMC: 10890151. DOI: 10.3390/life14020239.


Roles of gut microbes in metabolic-associated fatty liver disease.

Chen C, Ho H Tzu Chi Med J. 2023; 35(4):279-289.

PMID: 38035063 PMC: 10683521. DOI: 10.4103/tcmj.tcmj_86_23.


References
1.
Ren T, Zhu J, Zhu L, Cheng M . The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α. Nutrients. 2017; 9(3). PMC: 5372861. DOI: 10.3390/nu9030198. View

2.
Williams K, Fuller C, Dieleman L, DaCosta C, Haldeman K, Sartor R . Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology. 2001; 120(4):925-37. DOI: 10.1053/gast.2001.22470. View

3.
Hossain N, Kanwar P, Mohanty S . A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract. 2016; 2016:7109270. PMC: 4781972. DOI: 10.1155/2016/7109270. View

4.
Dowman J, Tomlinson J, Newsome P . Pathogenesis of non-alcoholic fatty liver disease. QJM. 2009; 103(2):71-83. PMC: 2810391. DOI: 10.1093/qjmed/hcp158. View

5.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P . Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18):3313-3327. PMC: 6105174. DOI: 10.1007/s00018-018-2860-6. View